



December 20, 2016

Novartis Pharma AG  
CH-4002, Basel, Switzerland

Reference: EudraCT 2010-024394-39/ Novartis Protocol ID CBEZ235B2201

*A Phase II study of orally administered BEZ235 monotherapy in patients with hormone receptor positive, HER2 negative, metastatic breast cancer, with or without PI3K activated pathway*

Trial CBEZ235B2201 was cancelled with no patient enrollment and as such, no results will be reported.